1 Deeply Undervalued Stock to Buy in the Market Correction

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. However, the company took another dive this year along with the broader market; President Donald Trump's trade wars are leaving few stocks completely unscathed.There is a silver lining, though, at least for investors focused on the long game. At these levels, Pfizer's shares might just be a steal. Here's why the stock is worth buying today.The Trump administration has so far spared pharmaceuticals from its announced tariffs, but has threatened several times to impose some on the industry. Like many other drugmakers (and companies in other sectors, for that matter), Pfizer likely prefers doing much of its manufacturing abroad because it's cheaper. However, tariffs defeat that purpose, and if they're eventually levied on the pharmaceutical industry -- as some CEOs think they will be -- Pfizer might be well equipped to handle them due to its significant existing manufacturing capacity in the U.S.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool